Rite Aid said it expects its pharmacy sourcing deal with McKesson as well as new and higher-priced generic drugs to drive sales in 2015.
G FarmaLabs received an offer of $100 million for a 20% stake in his company from an investment firm he met at the CannaBusiness Money Show in Boston last week.
Penny stock publisher Peter Leeds finds most pot companies to be very high risk and cautions investors to wait until prices drop.
Rite Aid (RAD) is moving higher ahead of its fourth-quarter report before the bell Thursday, April 10. The third-largest drugstore chain in the U.S. is expected to report revenue of $6.54 billion over the three months to February, a 1.4% year-over-year gain, according to analysts surveyed by Thomson Reuters.
Conatus Pharmaceuticals is an early-stage developer of drugs to treat diseases of the liver with a favorable risk-reward profile, particularly after recent investor selling in the biotech sector has created some nice values.
But in the real world they're wrong, as the Questcor buyout demonstrates.
An inside look at how Intuitive Surgical botched the upgrade cycle for its high-price surgical robots.
If approved next year, Alkermes' aripiprazole lauroxil will compete against several other long-acting antipsychotics, including a similar once-monthly injectable aripiprazole approved last year and sold by Otuska and Lundbeck. But the schizophrenia treatment market (oral and injectable drugs) is big and growing -- more than $11 billion in the U.S. last year and $20 billion-plus worldwide. Oral versions of aripiprazole, sold under the brand name Abilify, generated $6.5 billion in sales last year.
U.S. stock futures point to a slight rebound on Wall Street; Citigroup to pay $1.13 billion to settle mortgage claims; Japan's Takeda and Eli Lilly are ordered to pat $9 billion in diabetes-drug case; Alcoa to report earnings on Tuesday.
Mallinckrodt will gain Questcor's lucrative drug Acthar Gel, which treats autoimmune and inflammatory diseases. Sales of the drug jumped about 50% year-over-year in 2013.
Questcor Pharmaceuticals has been a controversial stock for years, as short selling research firm Citron Research raised concerns about the company's Acthar gel, which is marketed for multiple sclerosis and other autoimmune and inflammatory disorders.
TheStreet's Jim Cramer is asked for advice on Mannkind, which has doubled in value after an FDA panel recommended approval of its insulin drug Afreeza.
Whenever you see a deal like Mallinckrodt buying Questcor, you have to ask: Is this a case of smart seller, dumb buyer? I've done zero work on Questcor, but over the past few years I've talked to a few very serious short-sellers who have. When I saw the news this morning, the first thing that crossed my mind: Mattel buying The Learning Company....Hewlett Packard buying Autonomy...Medtronic buying Arterial Vascular Engineering. All three of the targets were the focus of short-sellers, and all three famously blew up, or otherwise caused havoc, once inside the new parent -- for the very reason the short-sellers had been short. Mattel was perhaps the most wounded, and almost taken down by what it found once it owned The Learning Company. No idea if that will happen here, but a quick peek at Mallinckrodt's history sure is a twisted tale....
Shares of Questcor surge before market open on Monday after it announces a $5.6 billion deal to be acquired by Mallinckrodt.
A majority of investors on StockTwits.com say the biotech sector is oversold. And they're looking to buy in for a bounce-back.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV